Ignite Creation Date:
2024-05-06 @ 5:58 PM
Last Modification Date:
2024-10-26 @ 2:39 PM
Study NCT ID:
NCT05495893
Status:
RECRUITING
Last Update Posted:
2022-08-10
First Post:
2022-07-25
Brief Title:
MMF Versus CYC in the Induction Therapy of Pediatric Active Proliferative LN
Sponsor:
Second Xiangya Hospital of Central South University
Organization:
Second Xiangya Hospital of Central South University
Study Overview
Official Title:
Mycophenolate Mofetil Versus Cyclophosphamide in the Induction Therapy of Pediatric Patients With Active Proliferative Lupus Nephritis A Prospective Randomized Multicenter Open-label Parallel-arm Study
Status:
RECRUITING
Status Verified Date:
2022-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
MyCITS
Brief Summary:
A prospective randomized multicenter open-label parallel-arm Study to compare effectiveness of mycophenolate mofetil versus cyclophosphamide in the Induction Therapy of pediatric patients with Active Proliferative Lupus Nephritis in Chinese population
Detailed Description:
Scattered research in adults showed that both mycophenolate mofetil MMF and cyclophosphamide CYC can be used in the induction therapy of lupus nephritis however data is limited in childrenTherefore the purpose of this study is to observe and compare the efficacy and safety of MMF and CYC as induction therapy for children with proliferative lupus nephritis through a multi-center open randomized controlled study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None